Enclomiphene, a selective oestrogen receptor modulator, has been making waves in fitness circles, with rumours swirling about its use by high-profile individuals like Jeff Bezos. While unconfirmed, these claims have sparked curiosity about the merits and risks associated with enclomiphene and its potential impact on health. So what is the truth?
One potential merit of enclomiphene lies in its hormonal regulation properties. Traditionally used in the treatment of female infertility, enclomiphene’s ability to modulate oestrogen receptors has led to speculation about its impact on testosterone production. In theory, increased testosterone levels could promote muscle growth, enhance strength, and improve overall physical performance.
Another suggested benefit of enclomiphene is its potential impact on body composition. Animal studies have indicated that enclomiphene might aid in reducing fat mass while increasing lean muscle mass. Although these findings require further validation in human studies, they offer an intriguing prospect for individuals seeking to optimise their physique.
Furthermore, enclomiphene’s mechanism of action, indirectly increasing testosterone production, is significant. Testosterone plays a vital role in various physiological processes, including muscle development, bone density, and energy levels. If enclomiphene can safely and effectively boost testosterone levels, it holds promise for those aiming to improve their fitness and overall health.
While enclomiphene shows potential, it is crucial to consider the associated risks and caveats. First and foremost are the potential side effects. Like any medication, enclomiphene can cause undesirable effects such as hot flashes, mood swings, headaches, and digestive issues. Prolonged use in high doses may lead to severe consequences, including liver damage and increased cardiovascular risks.
Furthermore, the legal and ethical implications of using enclomiphene off-label should not be ignored. While the FDA has approved enclomiphene for the treatment of female infertility, its use for enhancing athletic performance or fitness is not authorised. Engaging in such off-label use raises ethical concerns and potential legal repercussions.
Lastly, the scientific consensus on enclomiphene’s efficacy and safety for fitness and health enhancement remains limited. Existing studies are constrained in scope, and the results lack universal consistency. More robust research is needed to establish a comprehensive understanding of enclomiphene’s benefits and potential drawbacks
